hsa-miR-203 enhances the sensitivity of leukemia cells to arsenic trioxide
Open Access
- 27 February 2013
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 5 (5), 1315-1321
- https://doi.org/10.3892/etm.2013.981
Abstract
The aim of this study was to investigate the effect of a eukaryotic expression vector expressing hsa-miR‑203 on the sensitivity of K562 leukemia cells to arsenic trioxide (ATO) and the possible mechanism of action. The eukaryotic expression vector expressing the hsa-miR‑203 plasmid (PmiR-203) was transfected into K562 cells using Lipofectamine 2000. bcr/abl 3' untranslated region (UTR) and bcr/abl mutated 3'UTR dual luciferase report vectors (psi-CHECK-2) were used to validate the regulation of bcr/abl by miR-203. The inhibitory effects of ATO and PmiR-203, used singly or in combination, on cell proliferation were detected by MTT assay. Apoptosis of the K562 cells was detected by flow cytometry using double-staining with Annexin V and propidium iodide (PI). The activities of caspase-3 and caspase-9 were detected by a colorimetric method and the cytochrome c protein levels were detected by western blotting. When used in combination with PmiR-203, the IC50 of ATO was reduced from 6.49 to 2.45 µg/ml and the sensitivity of cells to ATO increased 2.64‑fold. In addition, PmiR-203 and ATO caused growth inhibition, apoptosis and G1-phase arrest in K562 cells. Furthermore, PmiR-203 significantly promoted ATO-mediated growth inhibition and apoptosis, affecting the G1 phase. JC-1 fluorescent staining revealed that the membrane potential of the mitochondria had changed. The activities of caspase-3 and caspase-9 increased, the expression levels of cytochrome c were upregulated and the expression level of bcr/abl mRNA was significantly suppressed. Furthermore, the dual-luciferase reporter vector, containing tandem miR-203 binding sites from the bcr/abl 3'UTR, demonstrated that bcr/abl was directly regulated by miR-203. PmiR-203 sensitized K562 leukemia cells to ATO by inducing apoptosis and downregulating bcr/abl gene levels. The induction of apoptosis may occur through the mitochondrial pathway. The combination of ATO and PmiR‑203 presents therapeutic potential for chronic myelogenous leukemia.Keywords
This publication has 13 references indexed in Scilit:
- miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescenceBritish Journal of Cancer, 2012
- MicroRNA-203 Expression as a New Prognostic Marker of Pancreatic AdenocarcinomaAnnals of Surgical Oncology, 2010
- MicroRNA: Potential Targets for the Development of Novel Drugs?Drugs in R&D, 2010
- Anti‐miR‐21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosisCancer Science, 2010
- miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinomaCarcinogenesis: Integrative Cancer Research, 2009
- Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survivalInternational Journal of Cancer, 2009
- Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene ExpressionCancer Cell, 2008
- A skin microRNA promotes differentiation by repressing ‘stemness’Nature, 2008
- Expanding the use of arsenic trioxide: Leukemias and beyondSeminars in Hematology, 2002
- Structural Basis for the Inhibition of Caspase-3 by XIAPCell, 2001